Fscig Hyqvia denied as non-formulary by Cigna?

Cigna's specific coverage criteria for fscig hyqvia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies HyQvia as Non-Formulary

Cigna's formulary places specialty immunoglobulin products on specific tiers, and the tier assignment for HyQvia may differ from other SCIG or IVIG products on the plan. A non-formulary denial for HyQvia typically means the plan has a preferred immunoglobulin product or route of administration that it expects patients to use first, and HyQvia was submitted without documenting why the preferred option is not appropriate. This is an administrative classification, not a clinical finding.

## Why This Denial Is Appealable

Formulary exceptions are a legally required part of every insurer's coverage process under ACA §2719 and most state pharmacy benefit laws. If Cigna's preferred immunoglobulin product is not clinically appropriate for your specific situation — due to tolerability, frequency-of-administration constraints, vascular access difficulties, or other documented clinical factors — a formulary exception appeal can authorize HyQvia as the medically necessary alternative. These appeals succeed when the prescriber clearly documents why the preferred product cannot be used.

## Federal Appeal Framework

• Formulary exception / internal appeal: File a formulary exception request, which triggers internal review under ERISA §503. Submit alongside or as part of a formal internal appeal if the initial exception request was denied.
• External review: Available under ACA §2719 after internal exhaustion; approximately four months to file. Particularly strong when the clinical record clearly shows that preferred alternatives are not appropriate for this patient.
• Expedited track: Request if your immunodeficiency creates urgent clinical need for the specific product and route.

## Documentation to Gather

1. Preferred formulary alternative history — for each immunoglobulin product Cigna lists as preferred, document whether it was tried (with dates and outcomes), is contraindicated, or is otherwise clinically inappropriate, with the prescriber's documented rationale. 2. Clinical rationale for HyQvia — records and prescriber notes explaining the specific clinical benefit of HyQvia's facilitated SCIG approach for this patient (vascular access, infusion frequency, home administration feasibility, prior tolerability issues). 3. Diagnosis and treatment necessity — immunology records confirming the underlying condition and the established need for immunoglobulin replacement therapy. 4. Prescriber formulary exception letter — a letter from your immunologist addressing each of Cigna's formulary exception criteria, explaining why HyQvia is medically necessary and preferred alternatives are not appropriate.

## Criteria-Mapping Structure

Request Cigna's formulary exception criteria and the list of preferred immunoglobulin products. In your appeal, address each preferred product by name and state whether it was used (with dates and outcomes) or why it cannot be used. Then map the clinical basis for HyQvia to each exception criterion. This structure directly answers what Cigna needs to approve the exception.